Latest:
Dr. Gandara on Incorporating MRD Testing into Lung Cancer Practice
David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David R. Spigel, MD, Sarah Cannon Research Institute
Latest:
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial
David R. Spigel, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the phase 3 PACIFIC trial of durvalumab treatment after chemotherapy in patients with unresectable stage III non-small cell lung cancer
David Reardon, MD, Dana-Farber Cancer Institute
Latest:
Rapid Readouts: Results of the SCOUT and NAVIGATE Trials
David A. Reardon, MD, presents slides, shown at the 2021 American Society of Clinical Oncology Annual Meeting, from the phase 2 NAVIGATE basket trial and the phase 1/2 SCOUT trial in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion–positive primary central nervous system (CNS) tumors treated with larotrectinib with or without prior therapy.
David Ross Camidge, MD, PhD
Latest:
Dr. Camidge on Biomarker Combinations in NSCLC
David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses biomarker combinations in non–small cell lung cancer (NSCLC).
David S. Hong, MD
Latest:
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Dr. David S. Hong presents the preliminary Phase 1 results on RMC-9805, a first-in-class, oral, RAS(ON) G12D-selective inhibitor, highlighting its promising safety, pharmacokinetics, and early antitumor activity in patients with KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC), with further dose optimization and combination studies underway.